StockData
Arvinas, Inc. logo

Arvinas, Inc. (ARVN) stock analysis

ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$6.87−0.04 (-0.58%)

Close on Nov 12, 2026Market cap $449.20MP/E 42.9Yield –

StockData Score

Prices as of Nov 12, 2026How the score works

Value1Growth1Performance3Health3Dividend0

Weak8 of 30 checks passed

Arvinas passes 8 of the 30 checks behind our score; 16 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
1/6
Past performance
3/6
Financial health
3/6
Dividend
0/6

What stands out

  • Low debt

    Debt is 0.1% of shareholders' equity, under the 40% we consider low.

  • Revenue growing 10%+ a year

    Revenue grew 26.0% a year over the last three fiscal years.

  • P/B below the industry

    Arvinas's price-to-book of 0.80 is below the Drugs median of 2.20.

  • Return on equity above the industry

    Arvinas's return on equity of 1.6% is above the Drugs median of -58.0%.

What to watch

  • Return on equity under 15%

    Return on equity was 1.6% over the last twelve months and averaged -35.5% over five years; we look for 15% on both.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -41400% of total debt; we look for at least 20%.

  • Elevated bankruptcy risk

    The Altman Z-score is 0.67; above 3 is the safe zone and below 1.8 the distress zone.

  • P/E above the industry

    Arvinas's P/E of 42.9 is above the Drugs median of 25.0.

Valuation1/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E above the industry

    Arvinas's P/E of 42.9 is above the Drugs median of 25.0.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    Arvinas's price-to-book of 0.80 is below the Drugs median of 2.20.

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth1/6

  • Revenue growing 10%+ a year

    Revenue grew 26.0% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -15.0% over the last twelve months; the Drugs median is 7.6%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin trend

    This company does not report gross profit.

Past performance3/6

  • Return on equity under 15%

    Return on equity was 1.6% over the last twelve months and averaged -35.5% over five years; we look for 15% on both.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity above the industry

    Arvinas's return on equity of 1.6% is above the Drugs median of -58.0%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was 2.9% over the last twelve months, against a 5-year average of -229%.

  • Net margin above the industry

    Arvinas's net margin of 2.9% is above the Drugs median of -53.5%.

Financial health3/6

  • Low debt

    Debt is 0.1% of shareholders' equity, under the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 0.3% five years ago to 0.1%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -41400% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 7.91 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is 0.67; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Arvinas has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Arvinas. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 2.6
  • Drugs median 2.2

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Medium risk

Average value traded per day
$6.09M
Value traded per 1% price move
$2.30M

Downside

High risk

Typical loss in a bad month
25.9%
Volatility (annualized)
56%
Sharpe ratio, 1 year
-0.77
Beta to the S&P 500 (5Y)
1.40

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2016 to 2025

Operating margin

-45.1%+421.3 pts over 5 years

Net margin

-30.8%+429.8 pts over 5 years

See a number that looks wrong?